Tratamiento intensificado sin bomba de insulina en pediatría

Referencias

1. Imagawa A, Toshiaki H, Jun-ichiro M, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and absence of diabetes-related antibodies. N Engl J Med 2000;342:301–7. 12.

2. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 1998;47(12):1857–66.

3. DCCT Research Group. The effects of intensive diabetes treatment on the development and progression of long-term complication in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med 1993;329: 977–86.

4. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. J Pediatr 1994;125:177–88.

5. DCCT Research Group, EDIC Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the diabetes control and complications trial (DCCT). J Pediatr 2001;139(6):804–12.

6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progressionof diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159–67.

7. Lind M, Oden A, Fahlen M, et al. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010;53:1093–8.

8. Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes. A statement of the American Diabetes Association. Diabetes Care 2005;28(1):186–212.

9. Rewers M, Pihoker C, Donaghue K, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2009; 10(Suppl 12):71–81.

10. Tamborlane WV, Sikes KA.Insulin therapy in children and adolescents. Endocrinol Metab Clin North Am. 2012, 41:145-60.

11. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18(3):192–200.

12. Cengiz E, Sherr JL, Erkin-Cakmak A, et al. A bridge to insulin pump therapy: bid regimen with NPH and detemir insulin during initial treatment of youth with type 1 diabetes (T1D). Endocr Pract 2011;6:1–17.

13. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28(4):950–5.
14. Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother 2005;6(4):1–9.

15. Owens DR, Bolli GB. Beyond the era of NPH insulin—long-acting insulin analogs: chemistry comparative pharmacology, and clinical application. Diabetes Technol Ther 2008;10:333–49

16. Mooradian A, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145(2):125–34.

17. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001;22:706–17.

18. Angostad HJ, Danne T, Deeb LC, et al. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009;10(Suppl 12):82–99.